Condor Research supplies lyophilized (freeze-dried) research peptides across Europe as COA-verified reference compounds for laboratory use only. Operated by Atrio Sciences s.r.o. in Slovakia, we third-party test every batch through an independent EU laboratory in Czechia and ship from an EU warehouse. This page explains what lyophilization is, why it matters for peptide research, and which flagship compounds are available.
This page is written for laboratory research contexts only. It contains no human or veterinary dosing guidance, no therapeutic claims, and no consumption instructions. All materials are supplied for research use only (RUO).
What is a lyophilized peptide?
Lyophilization — commonly called freeze-drying — is a dehydration process in which a compound is first frozen and then placed under vacuum so that the ice sublimes directly to vapour, bypassing the liquid phase. What remains is a dry, porous solid: the peptide matrix without its water shell.1
For peptide reference compounds, the significance of that water removal is chemical. In aqueous solution, peptides are subject to several degradation pathways: hydrolytic cleavage of peptide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine or cysteine side chains, and — in longer chains — aggregation driven by exposed hydrophobic segments. The kinetics of every one of these pathways is sensitive to molecular mobility, which in turn depends on the presence of water. Remove the water, immobilise the matrix into an amorphous glassy solid, and you suppress the mobility that drives these reactions.2
Remove the water, immobilise the matrix — and you suppress the molecular mobility that drives peptide degradation. That is the entire logic of lyophilization as a preservation strategy.
The practical consequence: a lyophilized peptide stored at –18 °C in a sealed, desiccated vial is chemically stable over timescales that are inaccessible to the same compound in solution. This is why essentially all precision reference peptides supplied for research are presented in lyophilized form rather than as pre-dissolved solutions.3
Why lyophilized format matters for laboratory research
A research compound is only as reliable as the purity that reaches your bench. Transport and storage conditions affect that purity; so does the time the compound spends in solution before use. Lyophilized format addresses both.
| Property | Lyophilized solid | Pre-dissolved solution |
|---|---|---|
| Shelf life | Extended — years at –18 °C when sealed; degradation kinetics suppressed by low molecular mobility | Limited — typically days to weeks at 2–8 °C depending on peptide, pH and excipients |
| Transport tolerance | Dry solid tolerates temperature excursions during shipping far better than aqueous solution | Cold-chain dependent; temperature breaks can accelerate aggregation and hydrolysis |
| Hydrolysis risk | Minimal in dry state; water required for hydrolytic cleavage of peptide bonds | Present from the moment of dissolution; rate determined by pH, temperature, buffer composition |
| Aggregation risk | Suppressed in amorphous solid matrix | Can develop on standing, especially at higher concentrations |
| Analytical traceability | HPLC purity and MS identity characterised on the dry material; COA directly describes what you receive | Purity refers to concentrated stock; diluted solutions are not independently verified |
| Flexibility of use | Researcher chooses diluent, concentration, and preparation timing to match study design | Concentration and formulation fixed; less experimental control |
Summary comparison for laboratory research contexts. Neither format implies or enables human use. All materials RUO only.
Lyophilization, reconstitution, and analytical documentation
The lyophilized solid is not the final form used in a laboratory experiment — it is the starting point. Before use in an in vitro assay or cell-culture model, the researcher reconstitutes the material by adding an appropriate diluent. The choice of diluent matters: bacteriostatic water is widely used for research peptide reconstitution because the antimicrobial agent (benzyl alcohol, typically 0.9%) inhibits microbial growth in the reconstituted solution; acetic acid or sterile water are alternatives for compounds where benzyl alcohol is known to interfere. For a detailed treatment of diluent selection, see our guide on bacteriostatic water, acetic acid and sterile water for peptide reconstitution.
The analytical documentation — the Certificate of Analysis — pertains to the lyophilized material as shipped. It reports the purity of the dry solid by HPLC and confirms peptide identity by mass spectrometry. This is the specification the researcher can verify against the actual lot number; it does not govern what happens after reconstitution, which is the researcher’s domain and responsibility.
The COA documents the lyophilized solid as shipped. What you do with the material after reconstitution — concentration, diluent, timing — is a research variable, not something the COA can certify.
How Condor Research documents lyophilized peptide quality
Every batch of lyophilized peptide listed by Condor Research is tested by an independent third-party laboratory in Czechia before it is offered for sale. This is the full quality chain:
| What is documented | How |
|---|---|
| Purity | HPLC ≥99% for individual compounds; reported per component for combination blends |
| Identity | Mass spectrometry confirms observed molecular mass matches the expected peptide sequence |
| Lot traceability | COA carries the batch/lot number, linking analytical data to the exact material received |
| Independence | Testing performed by an EU laboratory separate from Condor Research — not internal QC |
| SDS / CLP | Safety Data Sheet with CLP hazard classification provided where applicable under REACH |
| Legal entity | Atrio Sciences s.r.o., IČO 57 669 651, Hornočermánska 1556/76, 949 01 Nitra, Slovakia |
We do not fabricate purity numbers or lot dates. If we cannot document it independently, we do not claim it.
Lyophilized peptide flagship compounds
The compounds below are among the most widely referenced in the preclinical peptide literature. Each is supplied as a lyophilized vial, third-party tested before listing. Research context is summarised from published literature and is preclinical throughout; none of these compounds is an approved drug in the EU for the research contexts described.
| Compound | Format | Primary research context (preclinical / in vitro) |
|---|---|---|
| BPC-157 | Synthetic pentadecapeptide · lyophilized vial | Investigated as a cytoprotective agent in gastrointestinal, vascular and musculoskeletal injury models.4 |
| TB-500 | Full-length thymosin β4 (43 aa) · lyophilized vial | Studied for actin sequestration, cell migration and angiogenesis in tissue-repair models.56 |
| GHK-Cu | Copper-binding tripeptide (Gly-His-Lys) · lyophilized vial | Examined in extracellular-matrix remodeling and wound-healing research.7 |
| Ipamorelin | Pentapeptide GH secretagogue · lyophilized vial | Investigated as a selective ghrelin-receptor agonist in growth-hormone-axis research.8 |
| CJC-1295 (no DAC) | GHRH analogue · lyophilized vial | Used alongside secretagogues in growth-hormone-axis in vitro models. |
| Epitalon | Khavinson bioregulator tetrapeptide · lyophilized vial | Examined in the peptide-bioregulator and telomere-research literature. |
| Semax | ACTH(4–7) derivative · lyophilized vial | A Russian regulatory neuropeptide studied in neuroprotection and cognition models. |
| Selank | Tuftsin analogue hexapeptide · lyophilized vial | Investigated in anxiolytic and immunomodulatory research models. |
| GLOW (GHK-Cu + BPC-157 + TB-500) | Combination blend · lyophilized vial | Multi-component repair-research blend; purity reported per component on the COA. |
| KLOW (GHK-Cu + BPC-157 + TB-500 + KPV) | Combination blend · lyophilized vial | Extended tissue-research blend adding KPV; purity per component. |
All vialled compounds supplied at ≥99% HPLC purity (individual) or per-component (blends), with independent EU laboratory testing and lot-specific COA. Evidence is overwhelmingly preclinical; no approved therapeutic indication applies in the EU for RUO contexts.
Browse by category
- Peptides in Vials — the full lyophilized vial catalog.
- Combination Blends — multi-component lyophilized blends with per-component purity documentation.
- Tissue Repair & Regeneration — BPC-157, TB-500, GHK-Cu, KPV and related compounds.
- Growth Hormone Secretagogues — the GH/IGF-axis research family.
EU shipping and logistics
Lyophilized compounds ship from our Slovakia warehouse within the EU via Packeta, DPD or DHL under DAP (Incoterms 2020). Free shipping applies on orders of €150 or more. Pricing is in EUR. The dry, cold-tolerant format means lyophilized vials are well-suited for international EU dispatch compared with liquid formats that require strict cold-chain continuity throughout transit.
Further reading in the research library
- How to Store and Reconstitute a Lyophilised Peptide: A Lab Handling Guide
- Bacteriostatic Water, Acetic Acid or Sterile Water? Choosing a Diluent
- What “99% Pure” on a Peptide COA Really Means
- Endotoxins and Sterility: The COA Section Almost Nobody Reads
- Research Peptides Europe — the full catalog and quality overview
- Quality & Third-Party Testing
Frequently asked questions
What does ‘lyophilized’ mean for a research peptide?
Lyophilization (freeze-drying) removes water from the compound by freezing it and then sublimating the ice under vacuum, leaving a dry, porous solid. In the solid state, the chemical reactions that degrade peptides in solution — hydrolysis, deamidation, oxidation, aggregation — are dramatically slowed because molecular mobility is reduced. The result is a reference compound with a longer and more predictable shelf life than an equivalent aqueous solution.2
How should I store a lyophilized peptide before reconstitution?
Keep the sealed vial in a freezer (–18 °C or colder) away from light. Avoid repeated freeze–thaw cycles of the sealed vial before you are ready to use it. Reconstitute only the amount needed for your experiment, using an appropriate diluent such as bacteriostatic water, and store the reconstituted solution at 2–8 °C. For a detailed guide on diluent selection, see Bacteriostatic Water, Acetic Acid or Sterile Water? and the full reconstitution guide.
What is the purity specification for your lyophilized peptides?
Individual compounds are specified at ≥99% HPLC purity. Combination blends are characterised per component. Peptide identity is confirmed by mass spectrometry. All specifications are documented in the lot-specific COA for each batch, available on the product listing.
Do you ship lyophilized peptides across the EU?
Yes. Inventory is held in our EU warehouse in Slovakia and dispatched within the EU via Packeta, DPD or DHL under DAP (Incoterms 2020), with free shipping on orders of €150 or more.
Are lyophilized peptides for human consumption?
No. All materials supplied by Condor Research (Atrio Sciences s.r.o.) are for in vitro and laboratory research use only (RUO). They are not drugs, foods or cosmetics, are not approved for human or veterinary use, and carry no therapeutic, diagnostic or consumption claims. We publish no dosing or “how to take” guidance.
Who performs the analytical testing?
An independent third-party laboratory based in Czechia — separate from Condor Research — characterises each batch for purity (HPLC) and identity (MS) before it is listed. The resulting Certificate of Analysis carries the batch/lot number so the data are traceable to the material you receive.
Who is Condor Research, legally?
Condor Research is operated by Atrio Sciences s.r.o., IČO 57 669 651, registered at Hornočermánska 1556/76, 949 01 Nitra, Slovakia. Questions: info@condorresearch.com.
All products supplied by Condor Research (Atrio Sciences s.r.o.) are for research use only / in vitro use. They are not for human or veterinary use, not drugs, foods or cosmetics, and not for diagnostic or therapeutic purposes. Nothing on this page constitutes dosing, medical or consumption advice.
Condor Research · Scientific desk
References
- Angkawinitwong U, et al. Solid-state protein formulations. Therapeutic Delivery. 2015 Jan;6(1):67–82. PMID: 25565441. https://pubmed.ncbi.nlm.nih.gov/25565441/
- Meyer JD, Manning MC. Effects of conformation on the chemical stability of pharmaceutically relevant polypeptides. Pharmaceutical Biotechnology. 2002;13:85–107. PMID: 11987755. https://pubmed.ncbi.nlm.nih.gov/11987755/
- Maa YF, Prestrelski SJ. Biopharmaceutical powders: particle formation and formulation considerations. Current Pharmaceutical Biotechnology. 2000 Nov;1(3):283–302. PMID: 11469385. https://pubmed.ncbi.nlm.nih.gov/11469385/
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157, Robert’s Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye’s Stress Coping Response. Gut and Liver. 2020 Mar 15;14(2):153–167. PMID: 31158953. https://pubmed.ncbi.nlm.nih.gov/31158953/
- Tokura Y, et al. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. Journal of Biochemistry. 2011 Jan;149(1):43–8. PMID: 20880960. https://pubmed.ncbi.nlm.nih.gov/20880960/
- Xue B, et al. Structural basis of thymosin-β4/profilin exchange leading to actin filament polymerization. Proceedings of the National Academy of Sciences USA. 2014 Oct 28;111(43):E4596–605. PMID: 25313062. https://pubmed.ncbi.nlm.nih.gov/25313062/
- Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969–88. PMID: 18644225. https://pubmed.ncbi.nlm.nih.gov/18644225/
- Jain D, et al. A review on parenteral delivery of peptides and proteins. Drug Development and Industrial Pharmacy. 2019 Sep;45(9):1403–1420. PMID: 31215293. https://pubmed.ncbi.nlm.nih.gov/31215293/